MX2024009960A - Inhibidores de receptor similar a la inmunoglobulina de celulas asesinas humanas, tres dominios de inmunoglobulina y cola citoplasmatica larga 3 (kir3dl3) y agentes activadores de celulas inmunes. - Google Patents

Inhibidores de receptor similar a la inmunoglobulina de celulas asesinas humanas, tres dominios de inmunoglobulina y cola citoplasmatica larga 3 (kir3dl3) y agentes activadores de celulas inmunes.

Info

Publication number
MX2024009960A
MX2024009960A MX2024009960A MX2024009960A MX2024009960A MX 2024009960 A MX2024009960 A MX 2024009960A MX 2024009960 A MX2024009960 A MX 2024009960A MX 2024009960 A MX2024009960 A MX 2024009960A MX 2024009960 A MX2024009960 A MX 2024009960A
Authority
MX
Mexico
Prior art keywords
kir3dl3
inhibitors
immune cell
cell activating
activating agents
Prior art date
Application number
MX2024009960A
Other languages
English (en)
Spanish (es)
Inventor
Scott Chappel
Detlev Biniszkiewicz
Bijan Etemad-Gilbertson
Original Assignee
Nextpoint Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nextpoint Therapeutics Inc filed Critical Nextpoint Therapeutics Inc
Publication of MX2024009960A publication Critical patent/MX2024009960A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024009960A 2022-02-22 2023-02-21 Inhibidores de receptor similar a la inmunoglobulina de celulas asesinas humanas, tres dominios de inmunoglobulina y cola citoplasmatica larga 3 (kir3dl3) y agentes activadores de celulas inmunes. MX2024009960A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263312507P 2022-02-22 2022-02-22
US202263418105P 2022-10-21 2022-10-21
PCT/US2023/013537 WO2023163956A2 (en) 2022-02-22 2023-02-21 Kir3dl3 inhibitors and immune cell activating agents

Publications (1)

Publication Number Publication Date
MX2024009960A true MX2024009960A (es) 2024-08-26

Family

ID=87766832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009960A MX2024009960A (es) 2022-02-22 2023-02-21 Inhibidores de receptor similar a la inmunoglobulina de celulas asesinas humanas, tres dominios de inmunoglobulina y cola citoplasmatica larga 3 (kir3dl3) y agentes activadores de celulas inmunes.

Country Status (9)

Country Link
US (1) US20250171533A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482526A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506731A (cg-RX-API-DMAC7.html)
KR (1) KR20250005988A (cg-RX-API-DMAC7.html)
AU (1) AU2023225596A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243330A1 (cg-RX-API-DMAC7.html)
IL (1) IL314839A (cg-RX-API-DMAC7.html)
MX (1) MX2024009960A (cg-RX-API-DMAC7.html)
WO (1) WO2023163956A2 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10829735B2 (en) * 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
KR102644544B1 (ko) * 2016-09-21 2024-03-11 넥스트큐어 인코포레이티드 Siglec-15를 위한 항체 및 이의 사용 방법
US20250388702A1 (en) * 2019-10-04 2025-12-25 Dana-Farber Cancer Institute, Inc. Anti-kir3dl3 antibodies and uses thereof
EP4037712A4 (en) * 2019-10-04 2023-11-01 Albert Einstein College of Medicine KIR3DL3 IS AN IMMUNE SYSTEM INHIBITANT RECEPTOR AND USES THEREOF

Also Published As

Publication number Publication date
AU2023225596A1 (en) 2024-08-08
IL314839A (en) 2024-10-01
EP4482526A4 (en) 2026-04-08
KR20250005988A (ko) 2025-01-10
WO2023163956A3 (en) 2024-03-14
JP2025506731A (ja) 2025-03-13
US20250171533A1 (en) 2025-05-29
WO2023163956A2 (en) 2023-08-31
CA3243330A1 (en) 2023-08-31
EP4482526A2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
PH12022500020A1 (en) Antibodies against sars-cov-2
WO2020168300A8 (en) Modified natural killer (nk) cells for immunotherapy
WO2018234793A3 (en) Antibodies
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
EP4410986A3 (en) Cells, vertebrates, populations & methods
ZA202309516B (en) Anti-ccr8 antibodies
PH12022550373A1 (en) Ex vivo gamma delta t cell populations
PH12017501748A1 (en) Antibodies to icos
WO2021127200A8 (en) Ilt3-binding agents and methods of use thereof
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MY188362A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
PH12021551475A1 (en) Heterodimeric proteins for modulating gamma delta t cells
WO2021262597A3 (en) Lair-1-binding agents and methods of use thereof
ZA202205927B (en) Anti-yellow fever virus antibodies, and methods of their generation and use
ZA202305072B (en) Cd1a antibodies and uses thereof
MX2021009626A (es) Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas.
WO2018120843A9 (zh) 一种三功能分子及其应用
CA3207182A1 (en) T cell therapy
MX2022000425A (es) Metodos y composiciones que comprenden un nivel reducido de proteinas de celulas hospedadoras.
JOP20220320B1 (ar) أجسام مضادة لـ pd-1
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
NZ741573A (en) Anti-cd43 antibody and use thereof for cancer treatment
WO2020232141A3 (en) Compositions and methods for treating t cell exhaustion
AU2019356414A8 (en) Binding proteins specific for HA-1H and uses thereof
ZA202401405B (en) Compositions and methods for anti-pacap antibodies